Disease Site Breast Disease You have free access to this content Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy : Risk factors of IBTR and validation of the MD Anderson Prognostic Index (pages 4385–4393)
Makoto Ishitobi, Shozo Ohsumi, Hideo Inaji, Shinji Ohno, Hideo Shigematsu, Futoshi Akiyama, Takuji Iwase, Sadako Akashi-Tanaka, Nobuaki Sato, Kaoru Takahashi and Shoji Oura
Version of Record online: 17 JAN 2012 | DOI: 10.1002/cncr.27377
Results from this study demonstrate that estrogen receptor status and multifocality after neoadjuvant chemotherapy (NAC) are independent predictors of ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy and that patients who develop IBTR after receiving NAC have significantly worse overall survival.
You have free access to this content Optimizing resource allocation for breast cancer prevention and care among Hong Kong Chinese women (pages 4394–4403)
Irene O. L. Wong, Janice W. H. Tsang, Benjamin J. Cowling and Gabriel M. Leung
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27448
Because of lower disease incidence and a difference in the age profile of Chinese patients, resources allocated to policies advocating earlier mass screening by mammography for the early diagnosis of breast cancer, instead, could be allocated more effectively and efficiently to patients with breast cancer by funding other breast cancer care-related interventions among Chinese women.
Gastrointestinal Disease You have free access to this content Loss of efficacy and cost-effectiveness when screening colonoscopy is performed by nongastroenterologists (pages 4404–4411)
Cesare Hassan, Douglas K. Rex, Angelo Zullo and Gregory S. Cooper
Version of Record online: 15 JUN 2012 | DOI: 10.1002/cncr.27664
When screening colonoscopy is performed by nongastroenterologist specialists, a relative 11% reduction in long-term colorectal cancer prevention rates may be expected compared with gastroenterologist endoscopists.
Genitourinary Disease You have free access to this content Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma (pages 4412–4420)
Simon P. Kim, Paul L. Crispen, R. Houston Thompson, Christopher J. Weight, Stephen A. Boorjian, Brian A. Costello, Christine M. Lohse and Bradley C. Leibovich
Version of Record online: 3 JAN 2012 | DOI: 10.1002/cncr.26695
With a substantial proportion of patients at risk of disease progression (DP) following nephrectomy for localized renal cell carcinoma, there are 6 ongoing adjuvant trials assessing the efficacy of targeted agents: ARISER, ASSURE, EVEREST, PROTECT, SORCE, and S-TRAC. Although each trial has differing pathologic inclusion criteria, this study found relatively similar and high accuracy in predicting DP. Overall, the ongoing adjuvant trials would include patients who develop DP 43% to 59% of the time and exclude patients who develop DP 6% to 18% of the time during follow-up from this study's retrospective cohort at the Mayo Clinic (Rochester, Minnesota).
You have free access to this content Disparities in access to care at high-volume institutions for uro-oncologic procedures (pages 4421–4426)
Quoc-Dien Trinh, Maxine Sun, Jesse Sammon, Marco Bianchi, Shyam Sukumar, Khurshid R. Ghani, Wooju Jeong, Ali Dabaja, Shahrokh F. Shariat, Paul Perrotte, Piyush K. Agarwal, Craig G. Rogers, James O. Peabody, Mani Menon and Pierre I. Karakiewicz
Version of Record online: 1 FEB 2012 | DOI: 10.1002/cncr.27440
On average, old, sick, poor, and Medicare patients are less likely to be treated at high-volume hospitals for uro-oncologic surgery. Selective referral of individuals who are less likely to receive care at such institutions may represent a health care priority intended to optimize outcomes across all population strata.
You have free access to this content Identification of anaplastic lymphoma kinase fusions in renal cancer : Large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method (pages 4427–4436)
Emiko Sugawara, Yuki Togashi, Naoto Kuroda, Seiji Sakata, Satoko Hatano, Reimi Asaka, Takeshi Yuasa, Junji Yonese, Masanobu Kitagawa, Hiroyuki Mano, Yuichi Ishikawa and Kengo Takeuchi
Version of Record online: 17 JAN 2012 | DOI: 10.1002/cncr.27391
The presence of oncogenic anaplastic lymphoma kinase fusions was demonstrated in a small subset of non–clear cell type renal cell carcinomas. This confirmed the potential of anaplastic lymphoma kinase inhibitor therapy for renal cell carcinoma.
You have free access to this content Circumcision and the risk of prostate cancer (pages 4437–4443)
Jonathan L. Wright, Daniel W. Lin and Janet L. Stanford
Version of Record online: 12 MAR 2012 | DOI: 10.1002/cncr.26653
Circumcision before first sexual intercourse is associated with a reduction in the relative risk of prostate cancer in this study population. The findings of this study are consistent with research supporting the infectious/inflammation pathway in prostate carcinogenesis.
Head and Neck Disease You have free access to this content Adenoid cystic carcinoma of the head and neck : Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data (pages 4444–4451)
Christopher L. Ellington, Michael Goodman, Scott A. Kono, William Grist, Trad Wadsworth, Amy Y. Chen, Taofeek Owonikoko, Suresh Ramalingam, Dong M. Shin, Fadlo R. Khuri, Jonathan J. Beitler and Nabil F. Saba
Version of Record online: 31 JAN 2012 | DOI: 10.1002/cncr.27408
The overall incidence of adenoid cystic cancer is declining. Females, patients with localized disease, and younger patients have significantly better survival across all time periods (all comparison-specific log-rank
P values <.001). Corrected by:
Erratum Vol. 118, Issue 21, 5448–5449, Version of Record online: 18 JUL 2012 You have free access to this content A population-based study of therapy and survival for patients with head and neck cancer treated in the community (pages 4452–4461)
Claudio Dansky Ullmann, Linda C. Harlan, Vickie L. Shavers and Jennifer L. Stevens
Version of Record online: 17 JAN 2012 | DOI: 10.1002/cncr.27419
Findings in particular tumor sites and stages may reflect the variability that still exists for the treatment of head and neck cancer. The use of taxanes and cetuximab will continue to increase based on new evidence of benefit.
Hematologic Malignancies You have free access to this content Predicting survival of patients with hypocellular myelodysplastic syndrome : Development of a disease-specific prognostic score system (pages 4462–4470)
Wei-Gang Tong, Alfonso Quintás-Cardama, Tapan Kadia, Gautam Borthakur, Elias Jabbour, Farhad Ravandi, Stefan Faderl, William Wierda, Sherry Pierce, Jianqin Shan, Carlos Bueso-Ramos, Hagop Kantarjian and Guillermo Garcia-Manero
Version of Record online: 17 JAN 2012 | DOI: 10.1002/cncr.27420
Hypocellular myelodysplastic syndrome (MDS) is not well characterized. The authors present an analysis of the largest cohort so far analyzed of hypocellular MDS and propose a disease-specific prognostic score.
You have free access to this content Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients (pages 4471–4477)
Stefan Faderl, Farhad Ravandi, Xuelin Huang, Xuemei Wang, Elias Jabbour, Guillermo Garcia-Manero, Tapan Kadia, Alessandra Ferrajoli, Marina Konopleva, Gautam Borthakur, Jan Burger, Jennie Feliu and Hagop M. Kantarjian
Version of Record online: 26 JAN 2012 | DOI: 10.1002/cncr.27429
Clofarabine plus low-dose cytarabine induction achieves complete remission in 58% of patients, with an 8-week mortality of 7%. Alternating this combination with decitabine during consolidation produces a median overall survival of 12.7 months and is therefore a valuable option for newly diagnosed patients with acute myeloid leukemia.
Lung Disease You have free access to this content Postoperative radiotherapy for elderly patients with stage III lung cancer (pages 4478–4485)
Juan P. Wisnivesky, Ethan A. Halm, Marcelo Bonomi, Cardinale Smith, Grace Mhango and Emilia Bagiella
Version of Record online: 13 FEB 2012 | DOI: 10.1002/cncr.26585
The potential role of postoperative radiation therapy for patients with completely resected, stage III nonsmall cell lung cancer who have N2 disease remains controversial. By using several methods to control for selection bias, the results from this study indicate that postoperative radiotherapy is not associated with improved survival in elderly patients with N2 disease.
You have free access to this content Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase ( ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancer (pages 4486–4494)
D. Ross Camidge, Mariana Theodoro, DeLee A. Maxson, Margaret Skokan, Tara O'Brien, Xian Lu, Robert C. Doebele, Anna E. Barón and Marileila Varella-Garcia
Version of Record online: 26 JAN 2012 | DOI: 10.1002/cncr.27411
False cellular negatives explain <100% cellular positivity rates in lung cancer positive for
ALK (anaplastic lymphoma kinase) as determined by fluorescence in situ hybridization (FISH). Neither percentage of positive cells nor signal copy number predict for benefit from ALK inhibition in ALK FISH–positive tumors. You have free access to this content The influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival : An analysis of the Survival, Epidemiology, and End Results database (pages 4495–4501)
Ali M. Saeed, Rebecca Toonkel, Marilyn K. Glassberg, Dao Nguyen, Jennifer J. Hu, Teresa A. Zimmers, David J. Robbins, Leonidas G. Koniaris and Brian E. Lally
Version of Record online: 23 APR 2012 | DOI: 10.1002/cncr.26686
By using the Surveillance, Epidemiology, and End Results database, the authors identify an association between Hispanic ethnicity and improved survival among patients with nonsmall cell lung cancer. Hispanic ethnicity also is associated with favorable histologic subtypes.
You have free access to this content Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer (pages 4502–4511)
Robert C. Doebele, Xian Lu, Christopher Sumey, DeLee A. Maxson, Andrew J. Weickhardt, Ana B. Oton, Paul A. Bunn Jr, Anna E. Barón, Wilbur A. Franklin, Dara L. Aisner, Marileila Varella-Garcia and D. Ross Camidge
Version of Record online: 26 JAN 2012 | DOI: 10.1002/cncr.27409
Patterns of metastatic spread were evaluated in patients with untreated nonsmall cell lung cancer following subclassification by
ALK, EGFR, and KRAS. ALK gene rearrangements were associated with metastases to the pericardium, pleura, and liver. You have free access to this content Prognostic implication of metastasis limited to segmental (level 13) and/or subsegmental (level 14) lymph nodes in patients with surgically resected nonsmall cell lung carcinoma and pathologic N1 lymph node status (pages 4512–4518)
Akiko Miyagi Maeshima, Koji Tsuta, Hisao Asamura and Hitoshi Tsuda
Version of Record online: 26 JAN 2012 | DOI: 10.1002/cncr.27424
The highest level of lymph node involvement can stratify the outcome of patients with nonsmall cell carcinoma who have pathologic N1 (pN1) lymph node status. Patients who have pN1 status with metastasis limited to segmental/subsegmental (level 13/14) lymph nodes have an intermediate 5-year disease-free survival rate between that of patients who have pN0 status and other patients with pN1 status.
Melanoma You have free access to this content Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma (pages 4519–4529)
Rajmohan Murali, Philip T. Brown, Richard F. Kefford, Richard A. Scolyer, John F. Thompson, Michael B. Atkins and Georgina V. Long
Version of Record online: 26 JUN 2012 | DOI: 10.1002/cncr.27693
This study of 2942 patients with stage IV melanoma indicates that, in addition to previously established clinical and pathologic factors, a history of multiple primary melanomas is an independent predictor of improved survival. A history of multiple primary melanomas should be incorporated into multivariate analyses of prognostic factors and treatment outcomes in patients with metastatic melanoma.
Neuro-Oncology You have free access to this content Dental x-rays and risk of meningioma (pages 4530–4537)
Elizabeth B. Claus, Lisa Calvocoressi, Melissa L. Bondy, Joellen M. Schildkraut, Joseph L. Wiemels and Margaret Wrensch
Version of Record online: 10 APR 2012 | DOI: 10.1002/cncr.26625
The authors report evidence of an increased risk of meningioma with exposure to dental x-rays, particularly for individuals who are exposed at a young age or with increased frequency. The results support the 2006 recommendations of the American Dental Association and highlight the finding that moderate use of this common and modifiable exposure may be of benefit to patients.
You have free access to this content Decreasing radiation therapy utilization in adult patients with glioblastoma multiforme : A population-based analysis (pages 4538–4544)
Gary V. Walker, Jing Li, Anita Mahajan, Mary Frances McAleer, John F. de Groot, Syed S. Azeem and Paul D. Brown
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27439
Patients with supratentorial World Health Organization grade IV glioblastoma in the Surveillance, Epidemiology, and End Results database from 1973 to 2006 are analyzed to determine the rate of radiation therapy utilization. The data show a decreasing utilization of radiation therapy in patients with glioblastoma over the past 16 years. Patients who are older, who are unmarried, and who have undergone biopsy only are less likely to receive radiation therapy.
You have free access to this content O 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide (pages 4545–4554)
Emmanuèle Lechapt-Zalcman, Guénaëlle Levallet, Audrey Emmanuelle Dugué, Anne Vital, Marie-Danièle Diebold, Philippe Menei, Philippe Colin, Philippe Peruzzy, Evelyne Emery, Myriam Bernaudin, Françoise Chapon and Jean-Sébastien Guillamo
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27441
6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and low MGMT expression are predictors of improved prognosis in patients with newly diagnosed glioblastoma who undergo surgical resection and receive carmustine-releasing wafer implants followed by a protocol of adjuvant radiotherapy and concomitant oral temozolomide chemotherapy. Soft Tissue and Bone Sarcoma You have free access to this content Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk (pages 4555–4563)
Akira Matsunobu, Reiko Imai, Tadashi Kamada, Takeshi Imaizumi, Hiroshi Tsuji, Hirohiko Tsujii, Yoshiyuki Shioyama, Hiroshi Honda, Shin-ichiro Tatezaki and for the Working Group for Bone and Soft Tissue Sarcomas
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27451
Carbon ion radiotherapy for 78 patients with unresectable osteosarcoma resulted in good local control and survival rates, especially for those with tumors <500 cm
3. The treatment provided good long-term functional results without unacceptable morbidity. You have free access to this content NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma (pages 4564–4570)
Seth M. Pollack, Achim A. Jungbluth, Benjamin L. Hoch, Erik A. Farrar, Marie Bleakley, David J. Schneider, Elizabeth T. Loggers, Eve Rodler, Janet F. Eary, Ernest U. Conrad, III, Robin L. Jones and Cassian Yee
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27446
The authors demonstrate that the cancer-testis antigen NY-ESO-1 is expressed in 100% of myxoid/round cell liposarcoma (MRCL) tumors tested and that MRCL cell lines can be recognized and specifically lysed by NY-ESO-1–specific effectors in vitro. These results establish NY-ESO-1 as an important target antigen for the treatment of patients with MRCL.
Discipline Clinical Trials You have free access to this content Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials (pages 4571–4578)
Rebecca D. Pentz, Margaret White, R. Donald Harvey, Zachary Luke Farmer, Yuan Liu, Colleen Lewis, Olga Dashevskaya, Taofeek Owonikoko and Fadlo R. Khuri
Version of Record online: 31 JAN 2012 | DOI: 10.1002/cncr.27397
Measurements using recent conceptual advances indicate a high proportion of therapeutic misconception (TM) but reveal a complex view of risks and benefits. Continuing to improve understanding of key TM concepts, with attention to risks from nontherapeutic research procedures, is important.
Disparities Research You have free access to this content Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer (pages 4579–4588)
Joseph M. Letourneau, James F. Smith, Erin E. Ebbel, Amaranta Craig, Patricia P. Katz, Marcelle I. Cedars and Mitchell P. Rosen
Version of Record online: 26 MAR 2012 | DOI: 10.1002/cncr.26649
Access to fertility counseling and fertility preservation has increased during the past decade for women in California who are survivors of reproductive age cancers. However, disparities with regard to age, education, ethnicity, gender identity, and parity may mark potential areas for improving access in the future.
Epidemiology You have free access to this content De novo acute myeloid leukemia risk factors : A Texas case-control study (pages 4589–4596)
Sara S. Strom, Robert Oum, Kplola Y. Elhor Gbito, Guillermo Garcia-Manero and Yuko Yamamura
Version of Record online: 1 FEB 2012 | DOI: 10.1002/cncr.27442
This case-control study indicates that several factors play a role in acute myeloid leukemia (AML) predisposition to possible joint effects. The results suggest that AML is a heterogeneous disease with sex-specific and subtype-specific risk factors that need to be considered when developing risk-prediction models.
Pediatric Oncology You have free access to this content Outcome for adolescent and young adult patients with osteosarcoma : A report from the Children's Oncology Group (pages 4597–4605)
Katherine A. Janeway, Donald A. Barkauskas, Mark D. Krailo, Paul A. Meyers, Cindy L. Schwartz, David H. Ebb, Nita L. Seibel, Holcombe E. Grier, Richard Gorlick and Neyssa Marina
Version of Record online: 17 JAN 2012 | DOI: 10.1002/cncr.27414
In children and young adults with osteosarcoma enrolled on North American cooperative group trials, age 18 to 30 years is associated with a statistically significant poorer outcome because of an increased rate of relapse. Poorer outcome in adolescent and young adult patients is not explained by tumor location, a higher incidence of poor histologic response, or metastatic disease at presentation.
Quality of Life You have free access to this content Psychometric validation of the female sexual function index (FSFI) in cancer survivors (pages 4606–4618)
Raymond E. Baser, Yuelin Li and Jeanne Carter
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.26739
The Female Sexual Function Index (FSFI) displays strong psychometric reliability and validity in this first validation of the instrument in cancer survivors. The results support its continued use for monitoring sexual function and cancer-related dysfunction among sexually active female cancer survivors.
Radiation Oncology You have full text access to this OnlineOpen article Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger (pages 4619–4626)
Bradford S. Hoppe, Romaine C. Nichols, Randal H. Henderson, Christopher G. Morris, Christopher R. Williams, Joseph Costa, Robert B. Marcus Jr, William M. Mendenhall, Zuofeng Li and Nancy P. Mendenhall
Version of Record online: 17 JAN 2012 | DOI: 10.1002/cncr.27398
We evaluated patient-reported health-related quality of life following proton therapy for prostate cancer in 262 men ≤60 years old. We found that these young men have excellent outcomes with respect to erectile dysfunction, urinary incontinence, and other health-related quality of life parameters during the first 2 years after treatment.
Supportive Care You have free access to this content A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries : Early therapy improves outcomes (pages 4627–4633)
Roy F. Chemaly, Karen J. Vigil, Mustafa Saad, Diana Vilar-Compte, Patricia Cornejo-Juarez, Carolina Perez-Jimenez, Sawsan Mubarak, Mohammed Salhab, Ying Jiang, Bruno Granwehr, Javier A. Adachi and Issam I. Raad
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27447
The 2009/H1N1 pandemic caused severe illness in immunocompromised patients with cancer who had solid tumors. The current study indicates that early initiation of antiviral therapy is crucial in this patient population to decrease morbidity and mortality.